REVIEW

Anandamide-Mediated Modulation of Nociceptive Transmission at the Spinal Cord Level

Diana SPICAROVA[1], Jiri PALECEK[1]

[1]Laboratory of Pain Research, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic

Summary

Three decades ago, the first endocannabinoid, anandamide (AEA), was identified, and its analgesic effect was recognized in humans and preclinical models. However, clinical trial failures pointed out the complexity of the AEA-induced analgesia. The first synapses in the superficial laminae of the spinal cord dorsal horn represent an important modulatory site in nociceptive transmission and subsequent pain perception. The glutamatergic synaptic transmission at these synapses is strongly modulated by two primary AEA-activated receptors, cannabinoid receptor 1 (CB_1) and transient receptor potential vanilloid 1 (TRPV1), both highly expressed on the presynaptic side formed by the endings of primary nociceptive neurons. Activation of these receptors can have predominantly inhibitory (CB_1) and excitatory (TRPV1) effects that are further modulated under pathological conditions. In addition, dual AEA-mediated signaling and action may occur in primary sensory neurons and dorsal horn synapses. AEA application causes balanced inhibition and excitation of primary afferent synaptic input on superficial dorsal horn neurons in normal conditions, whereas peripheral inflammation promotes AEA-mediated inhibition. This review focuses mainly on the modulation of synaptic transmission at the spinal cord level and signaling in primary nociceptive neurons by AEA *via* CB_1 and TRPV1 receptors. Furthermore, the spinal analgesic effect in preclinical studies and clinical aspects of AEA-mediated analgesia are considered.

Key words

Anandamide • CB_1 • TRPV1 • NAPE • Spinal cord • Synaptic transmission

Corresponding author

D. Spicarova, Laboratory of Pain Research, Institute of Physiology CAS, Videnska 1083, 142 00 Praha 4, Czech Republic. E-mail: Diana.Spicarova@fgu.cas.cz

Introduction

Pain modulation and analgesic effects of the endocannabinoid anandamide (AEA, *N*-arachidonoyl-ethanolamine) were recognized in humans and intensively studied in experimental rodent models [1-7]. However, the underlying mechanisms of AEA anti-nociceptive action still need to be understood better due to the complexity of the AEA metabolism, trafficking and storage, the whole endocannabinoid system balance, and AEA dual effects on sensory processing and signaling [8-10]. The scientific effort to understand and modulate AEA-mediated signaling at the spinal cord level has substantial implications for the development of new possible therapeutic strategies for pain relief.

Anandamide as a part of the endocannabinoid system and endocannabinoidome

The endocannabinoid system consists of classical cannabinoid CB_1 and CB_2 receptors, endo-cannabinoids – AEA and 2-arachidonoylglycerol (2-AG), and their synthesizing and degradation enzymes [11]. It exerts homeostatic function and controls a wide range of various physiological roles like emotional processing, learning and memory, sleep, appetite, cardiovascular functions, reproduction, temperature control, immune

response, inflammation and pain. The essential role of the endocannabinoid system in CNS is neuromodulation, affecting synaptic plasticity, as well as nociceptive synaptic transmission [12]. Imbalance or malfunction of endocannabinoid system is involved in nervous system disorders such as anxiety, depression, schizophrenia, multiple sclerosis, neurodegeneration, stroke, epilepsy, addiction, and pathological pain states [13-15].

Lately, a new concept of endocannabinoidome has been established (Fig. 1). The endocannabinoidome extends the boundaries of the endocannabinoid system to include endocannabinoid-like lipid mediators that are biochemically related to the endocannabinoids. These lipids include a family of *N*-acylethanolamines (NAEs), including *N*-palmitoylethanolamine (PEA), *N*-oleoyletha-nolamine (OEA), *N*-linoleoylethanolamine (LEA), *N*-docosahexaenoylethanolamine (DHEA), a family of 2-acylglycerols (2-oleoyl glycerol, 2-OG; 2-linoleoyl glycerol, 2-LG), *N*-acyl neurotransmitters (*N*-acyl dopamines, *N*-acyl serotonins) or also lipoamino acids (*N*-acyl taurines, *N*-acyl glycines). The endocanna-binoidome further encompasses enzymes for the mentioned bioactive lipids syntheses and degradation,

and their receptors, among others, orphan G-protein coupled receptors (GPR55, GPR110, GPR18 or GPR119), one of the key nociceptive receptors – transient receptor potential vanilloid 1 (TRPV1) or nuclear peroxisome proliferator-activated receptors PPARα and PPARγ [1]. Changes in AEA metabolism/level within the wider endocannabinoidome may alter metabolic pathways of other lipid mediators and modulate alternative signaling with an impact on physiological functions. The endocannabinoidome exerts a more comprehensive impact on health and body homeostasis and thus should also be considered in clinical studies related to AEA.

AEA is an arachidonic acid derivative, *N*-arachi-donoylethanolamine, a naturally occurring compound within the body belonging to the larger family of NAEs. It was the first endocannabinoid identified from the porcine brain and was later isolated and measured in humans and rats [16,17]. The word Ananda means bliss and happiness in Sanskrit, which fits well with current research that describes AEA-mediated signaling through the CB_1 receptor to produce analgesic, anxiolytic, and antidepressant effects [7,18-20].


Fig. 1. Endocannabinoidome receptors and mediators. Groups of endocannabinoid-like lipid mediators are distinguished in colors: *N*-acylethanolamines in red, 2-acylglycerols in black, *N*-acyl neurotransmitters in blue, and lipoamino acids in green. Abbreviations: 2-AG, 2-arachidonoylglycerol; AEA, *N*-arachidonoylethanolamine (anandamide); DEA, *N*-docosatetraenoylethanolamine; DHEA, *N*-docosahexaenoylethanolamine; HEA, *N*-homo-γ-linolenylethanolamine; LEA, *N*-linoleoylethanolamine; NADA, *N*-arachidonoyldopamine; OEA, *N*-oleoylethanolamine; OLDA, *N*-oleoyldopamine; PEA, *N*-palmitoylethanolamine. The image was created with BioRender.com.

AEA was initially identified to bind preferentially to the CB_1 receptor and with lower affinity to the CB_2 receptor [16]. Later, the activation of nonselective cation channel TRPV1 by AEA was recognized, while its efficacy at human TRPV1 was reported to be higher than that at rat TRPV1 [21,22]. Thus, AEA acts as an endocannabinoid and endovanilloid; the CB_1 and TRPV1 being the main AEA activated receptors. Other molecular targets affected by AEA were also recognized – including nuclear receptors PPARγ and PPARα, voltage-gated T-type calcium channels (Ca_V3) and sodium channels [23-27]. AEA activation of both CB_1 and TRPV1 receptors at the first nociceptive synapse in the spinal cord dorsal horn plays an important role in pain modulation. The action of AEA at this synapse is complex, as the effect of presynaptic CB_1 receptor activation on neurotransmitter release is inhibitory, and the main impact of TRPV1 activation is excitatory.

Anandamide metabolism

Under neuronal stimulation, AEA is produced in and released from neurons in a Ca^{2+}-dependent manner [28]. Furthermore, the Ca^{2+}-independent formation of AEA was later demonstrated after PKC and PAK activation in primary sensory neurons, also named dorsal root ganglion (DRG) neurons [29]. Redundant biosynthetic pathways of AEA were characterized; phospholipase A2 group IV E (PLA2G4E, cPLA2ε) was identified as Ca^{2+}-dependent N-acyltransferase (Ca-NAT), which catalyzes the formation of AEA precursor *N*-acylphosphatidylethanolamine (NAPE) from phosphatidylethanolamine (PE) and phosphatidylcholine (PC), with a transfer of the acyl group of PC to the amine of PE [30]. In brain lysate, Ca-NAT activity preferably generates N-arachidonoyl-containing (p)NAPEs with polyunsaturated acyl groups at the sn-2 position [1,31]. On the other hand, Ca^{2+}-independent N-acyltransferases (NATs) termed phospholipase A and acyltransferase (PLAAT) can also generate NAPE [32,33]. The main enzyme converting NAPE to AEA is *N*-acylphosphatidylethanolamine phospholipase D (NAPE-PLD), which catalyzes the AEA syntheses in a Ca^{2+}-sensitive manner [34]. But, AEA may also be synthesized from NAPE by other Ca^{2+}-insensitive enzymes [35].

In the CNS, the enzyme fatty acid amino hydrolase (FAAH) primarily degrades AEA to arachidonic acid and ethanolamine. It is important to note that it accepts multiple fatty acid amides as a substrate, including palmitoyl- and oleoyl-ethanolamide [36]. In addition to the hydrolytic pathway, AEA undergoes oxygenation by cyclooxygenase 2 (COX-2), 5-, 12-, 15-lipoxygenase (LOX) and cytochrome P450 monooxygenases to create prostaglandin-ethanolamides, hydroxyl-eicosatetraenoyl-ethanolamides (HETE-EAs) and epoxy-eicosatrienoyl-ethanolamide see for reviews [1,8].

Interaction between CB_1 receptor and TRPV1 channel signaling in DRG neurons

In nociceptive DRG neurons, an opposite role for CB_1 and TRPV1 receptor activation was suggested, while AEA may activate both and trigger complex effects. AEA acts as a low-efficacy TRPV1 agonist. The efficacy of AEA may be affected by the number of TRPV1 channels in the plasmatic membrane, their phosphorylation, AEA metabolism, efflux or uptake, trafficking, storage, and the critical role also plays the concomitant CB_1 receptor activation [8,37-41]. The AEA-mediated effects may differ based on the expression of the target receptors. Neurons expressing only CB_1 receptors or only TRPV1 channels may exert the opposite AEA-induced effects. In neonatal rat cultured neurons, the AEA-mediated inhibitory or excitatory effect was reported in size-segregated DRG populations of neurons. In supporting experiments, Ca^{2+} transients were evoked by KCl-induced depolarization and AEA application inhibited or potentiated these Ca^{2+} transients [42]. The CB_1 activation-mediated inhibitory effect on depolarization-induced Ca^{2+} transients was also shown in primary culture of adult DRG neurons, which additionally rarely responded to capsaicin [43]. The dual effect of AEA application on synaptic input from primary nociceptive fibers was demonstrated at the first nociceptive synapses formed by these nociceptive DRG endings in acute spinal cord slices [10].

However, CB_1 and TRPV1 receptors exhibit high co-expression within the DRG neurons [44-46], suggesting complex AEA-mediated regulation based on CB_1/TRPV1 crosstalk in these neurons. In transfected cells overexpressing both receptors, a dual effect of CB_1 activation on capsaicin evoked, TRPV1-mediated Ca^{2+} response was described. Activation of the CB_1 receptor inhibited or enhanced capsaicin-induced responses depending on the signaling pathways activated. Inhibition of TRPV1 channel responses was mediated by negative regulation of the cAMP signaling *via* CB_1 receptor activation. The opposite

effect, potentiation of TRPV1 channel responses, was mediated *via* phosphatidylinositol 3-kinase (PI3K) and phospholipase C (PLC) pathways stimulated by CB_1 receptor activation [47]. Meanwhile, the activation of diverse intracellular signaling cascades, such as PI3K, PLC-PKC or PKA are known to sensitize the TRPV1 channel to the agonist [38,41,48-53]. Further, it was shown that the constitutive activity of the CB_1 receptor maintains the TRPV1 channel in a sensitized state [54]. The effect of AEA thus depends on the activation/regulation of CB_1 and TRPV1 receptors and the concomitant CB_1-mediated regulation of specific intracellular signaling with an impact on the TRPV1 sensitization. The order in which individual receptors are activated could also play a role [47,54]. A later study suggested that CB_1-supported TRPV1 sensitization and the induction of TRPV1 responsiveness to AEA in DRG neurons may be underlined by the spatial proximity of both receptors [55].

On the other hand, reduction of TRPV1 sensitization after CB_1 receptor activation was also shown in experiments where AEA in subthreshold concentration for TRPV1 activation facilitated heat-induced Ca^{2+} transients that were further enhanced by CB_1 receptor inhibition. The Ca^{2+} transients induced by AEA in the concentration to activate TRPV1 were reduced by simultaneous CB_1 receptor activation by CB_1 agonist HU210 [56]. Capsaicin evoked TRPV1-mediated cationic influx was attenuated by CB_1 receptor activation, which in addition also reduced the number of capsaicin-responsive cells in these experiments [40,57]. Remarkably, experiments in spinal cord slices showed that AEA induced a concentration-dependent release of neuropeptide, calcitonin gene-related peptide (CGRP) and substance P (SP), *via* TRPV1 channel activation on central terminals of DRG neurons [58]. This TRPV1-mediated pronociceptive process of neuropeptide release in the dorsal horn was reduced by CB_1 activation [59]. Thus, AEA activation of CB_1 receptors on central terminals of DRG neurons may concomitantly affect the sensitization/activation of TRPV1 channels, and the final AEA effect could be concentration and receptors proximity dependent. In addition, the increase in intracellular Ca^{2+} concentration in DRG neurons stimulates the formation of endogenous AEA. Newly synthesized AEA was shown to mediate TRPV1-dependent Ca^{2+} influx subsequently. Thus, AEA was proposed to act as an intracellular messenger, amplifying intracellular concentration of Ca^{2+} *via* TRPV1 channels [39].

A fatty acid binding protein 5 (FABP5) is an intracellular carrier for AEA transport to FAAH-mediated hydrolyses. A conditional knockout strategy was used to selectively ablate FABP5 in the TRPV1 channel expressing DRG neurons. This genetic approach elevated AEA, PEA, and OEA levels in DRGs, while 2-AG levels remained unchanged. Elevated AEA levels in nociceptive DRGs after FABP5 deletion attenuated nerve growth factor-mediated TRPV1 sensitization *via* CB_1 receptor activation, and the emergence of antinociceptive effects mediated by CB_1 was thus revealed [60].

CB_1 and TRPV1 receptors modulation of transmitter release in spinal cord dorsal horn

The first synapses of the pain pathway are localized in the spinal cord dorsal horn, particularly in the superficial laminae. Nociceptive signaling from the periphery is transmitted from DRG neurons, to dorsal horn neurons, which convey signaling to higher brain areas. AEA acts on the CB_1 and TRPV1 receptors expressed at presynaptic endings of primary afferents and modulate neurotransmitter release. Activation of presynaptic CB_1 receptors decreases glutamate release by a well-established mechanism of trimeric $G_{i/o}$-protein cascade stimulation, inhibiting adenylyl cyclase, decreasing calcium conductance by inhibition of high-voltage activated N- and P/Q-type Ca^{2+} channels, and increasing the potassium conductance *via* stimulation of inwardly rectifying and A-type outward potassium channels (Fig. 2) [61,62]. In comparison, CB_1 receptor coupling to G_s-protein, stimulating adenylyl cyclase, was unmasked when the $G_{i/o}$-protein cascade was inhibited [63]. Whereas the isoform of adenylyl cyclase expressed in cells may be crucial in the CB_1 receptor activation-induced dual effect on adenylyl cyclase [64].

TRPV1 activation-mediated responses are characterized by two phenomena – desensitization and tachyphylaxis. During TRPV1 stimulation, the channel activity is Ca^{2+}-dependently reduced, and TRPV1 thus undergoes rapid desensitization. Tachyphylaxis occurs during repetitive agonist stimulation while the TRPV1-mediated responses are diminished. TRPV1 channel activation at presynaptic ending allows Ca^{2+} influx through the opened pore, increasing Ca^{2+} concentration in the cytosol and dramatically enhancing spontaneous glutmate release [65-67]. Potent TRPV1 agonist capsaicin application elicited action potentials in superficial dorsal horn neurons, but evoked glutamate release induced by electrical stimulation of the dorsal root was prevented [65,66]. Thus, the facilitation of spontaneous glutamate

Fig. 2. Simplified illustration of AEA action at the first nociceptive synapse formed by the central terminal of the primary sensory neuron and the secondary spinal cord dorsal horn neuron. Autocrine and retrograde signaling of AEA is suggested, whereas AEA is synthesized in addition to other enzymes by Ca^{2+}-dependent NAPE-PLD in both primary and secondary nociceptive neurons. (The contribution of glial cells to AEA signaling is not depicted). Translocation of the lipid molecule of AEA across the plasma membrane by diffusion and a membrane transporter was proposed. Intracellular carriers, including the fatty acid binding protein 5 (FABP5) and the heat shock protein 70 (HSP70), may facilitate the intracellular transport of AEA, for example, towards the FAAH for degradation. Two primary AEA-activated receptors are abundantly expressed on the presynaptic side, where they regulate glutamate release. At lower concentrations, the CB_1 receptor is suggested to be activated, while at higher concentrations, both the CB_1 and TRPV1 receptors are activated. In addition, AEA could directly inhibit low-voltage-activated calcium channels (Ca_V3) to modulate the excitability of neuron. The reduction in transmitter release after CB_1 receptor activation is attributed to the inhibition of high-voltage-activated calcium channels (VACC) and the activation of inwardly rectifying potassium channels (K_{ir}). The image was created with BioRender.com.

release by capsaicin was sufficient to transmit nociceptive information further along the pain pathway by activating second-order neurons even when the action potential-evoked glutamate release from primary afferent endings was blocked. Furthermore, *in vivo* electrophysiological experiments demonstrated that spinal administration of TRPV1 antagonist capsazepine reduced nociceptive fibers (Aδ- and C-) stimulation-evoked responses of dorsal horn neurons [68]. It is suggested that endogenous AEA primarily activates CB_1 receptors under normal conditions, and its concentration is insufficient for TRPV1 channel stimulation on the central endings of DRG neurons.

Modulation of synaptic transmission at first nociceptive synapses by anandamide

In the superficial spinal cord dorsal horn, the patch-clamp recording of the dorsal root electrical stimulation-evoked excitatory postsynaptic currents (eEPSCs) from lamina II neurons revealed inhibition of the eEPSC amplitude by AEA application. Meanwhile, AEA attenuated evoked excitatory transmission more effectively during Aδ-fiber than C-fiber stimulation. A similar decrease of eEPSC amplitude was demonstrated after the CB_1 receptor agonist WIN55,212-2 application [69,70]. The effects of AEA on spontaneous synaptic transmission were reported inconsistently, from no detected change in the frequency of miniature EPSC (mEPSC) [70] to a concentration-dependent effect of AEA [71]. In the latter experiments, mEPSCs were recorded, and the low AEA concentration-induced inhibition of frequency was suggested to be mediated *via* CB_1 receptors activation, and the higher AEA concentration-induced excitatory effect *via* TRPV1 channels [71].

A recent study evaluated AEA modulation by recording mEPSC from neurons in lamina I and II(outer) in

Fig. 3. Peripheral inflammation enhanced the inhibitory effect of AEA application on dorsal horn neurons mEPSC frequency in spinal cord slices. (**A, B**) Normalized frequency of mEPSC during acute AEA application (1 μM, 10 μM, and 30 μM, 4 min each concentration) in control conditions (A) and 24 h after induction of peripheral inflammation (B) by subcutaneous carrageenan injection. Statistical analysis showed a significant difference between control and inflammatory conditions in each AEA concentration tested (1 μM AEA, $p<0.05$; 10 μM AEA, $p<0.05$; 30 μM AEA, $p<0.05$). (**C**) Application of AEA induced decrease or increase of mEPSC frequency in a comparable number of superficial dorsal horn neurons in control conditions. The number of neurons with mEPSC frequency inhibition by AEA application was reduced after inhibition of the CB_1 receptor (PF514273 application) and especially after CB_1 and FAAH co-inhibition (PF514273/URB597 co-application) used as a pretreatment. (**D**) After peripheral inflammation, most neurons received synaptic input inhibited by the AEA application (73 %). Pretreatment with PF514273 and PF514273/URB597 reduced the inhibitory and enhanced the excitatory AEA-induced effect. Abbreviations: PF (PF514273, CB_1 receptor antagonist), SB (SB366791, TRPV1 antagonist), URB (URB597, FAAH inhibitor). The figure was adapted from Pontearso *et al.* [10].

acute slices [10]. The results suggested that applied AEA had a dual effect on mEPSC frequency with similar size populations of recorded neurons showing inhibition and excitation. This balanced AEA effect on mEPSC frequency was changed following peripheral inflammation when AEA-induced decrease of neurotransmitter release from primary afferent fibers (mEPSC frequency) was dominant (Fig. 3). The excitatory effect of AEA application was evident only when CB_1 receptors and FAAH were inhibited [10].

Notably, these described effects of exogenous AEA application contrast with those observed following the application of its precursor 20:4-NAPE, which increased levels of endo-genous AEA and consistently inhibited both action potential-dependent and -independent excitatory synaptic transmission, as evidenced by the recording of eEPSC, sEPSC, and mEPSC [9,72]. In these experiments, AEA was synthesized in spinal cord slices from 20:4-NAPE primarily by NAPE-PLD (Fig. 4) [72]. The 20:4-NAPE

mediated inhibition was also present after peripheral inflammation while the underlying mechanisms were altered. In naïve animals, the 20:4-NAPE effect was mediated by CB_1 receptors, but after inflammation, the TRPV1 channel-mediated mechanism was also involved [9,72]. The physiological mechanism of AEA syntheses by available catabolic enzymes, together with their cellular distribution and level of enzymatic activity, regulate AEA concentration locally and may have a crucial role in the AEA-induced modulation of nociception [9]. The local production of AEA from its precursor could thus be advantageous for analgesic purposes in clinical settings.


Fig. 4. Application of the AEA precursor 20:4-NAPE decreased excitatory synaptic transmission at the first nociceptive synapses *via* NAPE-PLD activation. Application of 20:4-NAPE (20 µM, 4 min) decreased the frequency of mEPSC (n = 15, *** p<0.001) recorded from superficial dorsal horn neurons in acute spinal cord slices. Incubation of slices with the NAPE-PLD inhibitor LEI-401 (1 µM, 2 h) prevented the effect of acutely applied 20:4-NAPE (20 µM, 4 min) on mEPSC frequency. The figure was adapted from Spicarova *et al.* [72].

Well-known endocannabinoid retrograde signaling described at synapses in the brain was also recognized in the spinal cord dorsal horn. Activation of spinal metabotropic glutamate receptor 5 ($mGluR_5$) stimulated endocannabinoid-mediated stress-induced analgesia by retrograde signaling *via* diacylglycerol lipase – 2-arachidonoylglycerol – CB_1 receptor pathway [73]. In other experiments different conditioning stimulation protocols known to induce endocannabinoid production and CB_1 receptor-dependent synaptic plasticity in other brain areas [74,75] were employed in spinal cord slices.

Low-frequency stimulation of primary afferent fibers combined with depolarization of postsynaptic neuron led to profound long-term depression mediated by CB_1 receptors [76]. These results indicated that CB_1 receptors activation in primary afferent fibers could prevent long-term potentiation underlying hypersensitive states.

Various populations of excitatory and inhibitory spinal interneurons form neuronal circuits in the dorsal horn and modulate the nociceptive signaling from the periphery. This signaling is also affected by descending modulation from higher brain areas. Many studies aimed at spinal nociception are performed in spinal cord slices. This preparation decreases the degree of complexity of spinal nociceptive signaling by eliminating functional descending pathways. Despite the expression on central terminals of primary sensory neurons, CB_1 receptors are also expressed in dorsal horn interneurons [44,73,77-79]. Their activation may decrease the inhibitory neurotransmitter release, leading to increased excitability of nociceptive dorsal horn neurons. Thus, an unexpected role of endocannabinoids acting on inhibitory interneurons as mediators of heterosynaptic pain sensitization was revealed in the dorsal horn [77].

Analgesia mediated by spinal anandamide

Treatment with cannabinoids induces analgesia by acting at the peripheral, spinal, and supraspinal levels [2,4,18,80,81]. Intrathecal (i.t.) administration of the CB_1 receptor antagonist, SR141716A, induced thermal hyperalgesia and facilitated responses of dorsal horn neurons evoked by transcutaneous electrical stimulation. These experiments suggested tonic activation of spinal CB_1 receptors modulating nociceptive threshold [82,83]. In comparison, i.t. administration as well as topical application of CB_1 receptor agonist WIN55,212-2 produced analgesia. When ineffective i.t. doses of WIN55,212-2 were used with topical tail immersion in the WIN55,212-2 solution, an antinociceptive effect was markedly potentiated. Thus, antinociceptive synergy occurred in both peripheral and spinal application sites [84]. Spinal administration of AEA had inconsistent effects on neuronal responses evoked by transcutaneous electrical stimulation of nociceptive primary afferent fibers in control animals. In contrast, under inflammatory conditions, AEA reduced these responses *via* CB_1 receptor activation [85]. Intrathecal application of WIN55,212-2 *via* activation of CB_1 receptors attenuated

mechanical hypersensitivity associated with peripheral inflammation induced by complete Freud's adjuvant (CFA) injection and also present after peripheral neuropathy caused by partial ligation of the sciatic nerve [86,87]. Increased AEA level in the spinal cord was reported in neuropathic pain model with chronic constriction injury (CCI) of the sciatic nerve [88]. Intrathecal AEA administration blocked carrageenan-induced thermal hyperalgesia [89] and CCI-induced mechanical allodynia *via* both CB_1 and TRPV1 receptor-dependent mechanisms [90]. Suppression of spinal AEA degradation by FAAH inhibition led to the TRPV1-mediated analgesic effect in neuropathic rats while supporting experiments indicated the lipoxygenase-mediated remodeling of AEA metabolism [91].

Clinical aspects of anandamide-mediated analgesia

Ongoing research focuses on the use of exo- and endo-cannabinoids to treat pain. Exocannabinoids, naturally occurring phytocannabinoids from the cannabis plant, and synthetic cannabinoids differentiate from endocannabinoids synthesized within the body in chemical structure and pharmacological properties upon activation of the classical cannabinoid receptors CB_1 and CB_2, reflecting their different origins. The beneficial effect of Sativex (Nabiximols), a cannabis-based pharmaceutical product containing Δ^9-tetrahydro-cannabinol (Δ^9-THC) and cannabidiol (CBD) approved for pain and spasticity treatment in patients with multiple sclerosis in 2005 in Canada, was confirmed in patients with peripheral neuropathic pain in further clinical trials [92,93]. The approval of Sativex encouraged further studies of new analgesics targeting the endocannabinoid system, modulating AEA levels and related signaling.

Clinical trials looking for AEA analgesic properties in pathological pain states and neurological disorders were supported by positive preclinical results [91,94,95]. However, the failure of these clinical trials testifies to the complexity of the AEA-induced effect, including the regulation of a wide range of physiological processes, which could underlie severe side effects. It also demonstrates the difficulty of the translation of promising results from animal models to clinical settings in humans. Several inhibitors of the AEA degradation enzyme FAAH entered clinical trials also with a focus on pain relief. These FAAH inhibitors elevated plasma AEA levels and were well tolerated [96]. However, clinical trials targeted at pain relief failed to produce analgesia in patients with osteoarthritic pain manifestation [97]. Clinical interest in this area waned when phase I of clinical trials testing BIA 10-2474 was terminated for tragic fatality in the group of volunteers receiving the highest dose [98]. Activity-based protein profiling revealed off-target BIA 10-2474 activities that may have contributed to the induced neurotoxicity [99]. However, the adverse effects of BIA 10-2474 remain unexplained [100]. The great hope of clinicians was to test peripherally restricted cannabinoid agonists based on preclinical research clearly showing the analgesic effects of peripheral cannabinoid receptor activation [2,3,81]. However, clinical trials using AZD1940 and AZD1704 have failed to produce any analgesic effect [101,102]. It is unclear if an optimal activation of CB_1 receptors to produce analgesia was achieved or if peripheral CB_1 receptor stimulation failed to inhibit nociceptive signaling [103]. A better understanding of the underlying mechanisms of AEA-induced effects and the differences between rodents and humans is essential to advance preclinical and translational research.

Conflict of Interest
There is no conflict of interest.

Acknowledgements

References

1. Mock ED, Gagestein B, van der Stelt M. Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities. Prog Lipid Res 2023;89:101194. https://doi.org/10.1016/j.plipres.2022.101194
2. Clapper JR, Moreno-Sanz G, Russo R, Guijarro A, Vacondio F, Duranti A, Tontini A, ET AL. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci 2010;13:1265-1270. https://doi.org/10.1038/nn.2632
3. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998;394:277-281. https://doi.org/10.1038/28393

4. Police A, Shankar VK, Pandey P, Rangappa S, Doerksen RJ, Narasimha Murthy S. Novel topical anandamide formulation for alleviating peripheral neuropathic pain. Int J Pharm 2023;641:123085. https://doi.org/10.1016/j.ijpharm.2023.123085

5. Habib AM, Okorokov AL, Hill MN, Bras JT, Lee MC, Li S, Gossage SJ, ET AL. Microdeletion in a FAAH pseudogene identified in a patient with high anandamide concentrations and pain insensitivity. Br J Anaesth 2019;123:e249-e253. https://doi.org/10.1016/j.bja.2019.02.019

6. Mikaeili H, Habib AM, Yeung CW, Santana-Varela S, Luiz AP, Panteleeva K, Zuberi S, ET AL. Molecular basis of FAAH-OUT-associated human pain insensitivity. Brain 2023;146:3851-3865. https://doi.org/10.1093/brain/awad098

7. Fride E, Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 1993;231:313-314. https://doi.org/10.1016/0014-2999(93)90468-W

8. Maccarrone M. Metabolism of the Endocannabinoid Anandamide: Open Questions after 25 Years. Front Mol Neurosci 2017;10:166. https://doi.org/10.3389/fnmol.2017.00166

9. Nerandzic V, Mrozkova P, Adamek P, Spicarova D, Nagy I, Palecek J. Peripheral inflammation affects modulation of nociceptive synaptic transmission in the spinal cord induced by N-arachidonoylphosphatidylethanolamine. Br J Pharmacol 2018;175:2322-2336. https://doi.org/10.1111/bph.13849

10. Pontearso M, Slepicka J, Bhattacharyya A, Spicarova D, Palecek J. Dual effect of anandamide on spinal nociceptive transmission in control and inflammatory conditions. Biomed Pharmacother 2024;173:116369. https://doi.org/10.1016/j.biopha.2024.116369

11. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, ET AL International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002;54:161-202. https://doi.org/10.1124/pr.54.2.161

12. Lu HC, Mackie K. An Introduction to the Endogenous Cannabinoid System. Biol Psychiatry 2016;79:516-525. https://doi.org/10.1016/j.biopsych.2015.07.028

13. Di Marzo V. The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders. Dialogues Clin Neurosci 2020;22:259-269. https://doi.org/10.31887/DCNS.2020.22.3/vdimarzo

14. Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol 2020;16:9-29. https://doi.org/10.1038/s41582-019-0284-z

15. Donvito G, Nass SR, Wilkerson JL, Curry ZA, Schurman LD, Kinsey SG, Lichtman AH. The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. Neuropsychopharmacology 2018;43:52-79. https://doi.org/10.1038/npp.2017.204

16. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, ET AL. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-1949. https://doi.org/10.1126/science.1470919

17. Felder CC, Nielsen A, Briley EM, Palkovits M, Priller J, Axelrod J, Nguyen DN, ET AL. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett 1996;393:231-235. https://doi.org/10.1016/0014-5793(96)00891-5

18. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, Krey JF, ET AL. An endocannabinoid mechanism for stress-induced analgesia. Nature 2005;435:1108-1112. https://doi.org/10.1038/nature03658

19. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Cassano T, ET AL. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A 2005;102:18620-18625. https://doi.org/10.1073/pnas.0509591102

20. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, ET AL. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003;9:76-81. https://doi.org/10.1038/nm803

21. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D, Hogestatt ED. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999;400:452-457. https://doi.org/10.1038/22761

22. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI, Chambers JK, ET AL. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 2000;129:227-230. https://doi.org/10.1038/sj.bjp.0703050

23. Chemin J, Nargeot J, Lory P. Chemical determinants involved in anandamide-induced inhibition of T-type calcium channels. J Biol Chem 2007;282:2314-2323. https://doi.org/10.1074/jbc.M610033200

24. Kim HI, Kim TH, Shin YK, Lee CS, Park M, Song JH. Anandamide suppression of Na+ currents in rat dorsal root ganglion neurons. Brain Res 2005;1062:39-47. https://doi.org/10.1016/j.brainres.2005.09.004

25. O'Sullivan SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 2007;152:576-582. https://doi.org/10.1038/sj.bjp.0707423

26. Okura D, Horishita T, Ueno S, Yanagihara N, Sudo Y, Uezono Y, Sata T. The endocannabinoid anandamide inhibits voltage-gated sodium channels Nav1.2, Nav1.6, Nav1.7, and Nav1.8 in Xenopus oocytes. Anesth Analg 2014;118:554-562. https://doi.org/10.1213/ANE.0000000000000070

27. Sun Y, Alexander SP, Garle MJ, Gibson CL, Hewitt K, Murphy SP, Kendall DA, Bennett AJ. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol 2007;152:734-743. https://doi.org/10.1038/sj.bjp.0707478

28. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994;372:686-691. https://doi.org/10.1038/372686a0

29. Vellani V, Petrosino S, De Petrocellis L, Valenti M, Prandini M, Magherini PC, McNaughton PA, Di Marzo V. Functional lipidomics. Calcium-independent activation of endocannabinoid/endovanilloid lipid signalling in sensory neurons by protein kinases C and A and thrombin. Neuropharmacology 2008;55:1274-1279. https://doi.org/10.1016/j.neuropharm.2008.01.010

30. Ogura Y, Parsons WH, Kamat SS, Cravatt BF. A calcium-dependent acyltransferase that produces N-acyl phosphatidylethanolamines. Nat Chem Biol 2016;12:669-671. https://doi.org/10.1038/nchembio.2127

31. Astarita G, Ahmed F, Piomelli D. Identification of biosynthetic precursors for the endocannabinoid anandamide in the rat brain. J Lipid Res 2008;49:48-57. https://doi.org/10.1194/jlr.M700354-JLR200

32. Jin XH, Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. Discovery and characterization of a Ca2+-independent phosphatidylethanolamine N-acyltransferase generating the anandamide precursor and its congeners. J Biol Chem 2007;282:3614-3623. https://doi.org/10.1074/jbc.M606369200

33. Tsuboi K, Uyama T, Okamoto Y, Ueda N. Endocannabinoids and related N-acylethanolamines: biological activities and metabolism. Inflamm Regen 2018;38:28. https://doi.org/10.1186/s41232-018-0086-5

34. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 2004;279:5298-5305. https://doi.org/10.1074/jbc.M306642200

35. Varga A, Jenes A, Marczylo TH, Sousa-Valente J, Chen J, Austin J, Selvarajah S, ET AL. Anandamide produced by Ca(2+)-insensitive enzymes induces excitation in primary sensory neurons. Pflugers Arch 2014;466:1421-1435. https://doi.org/10.1007/s00424-013-1360-7

36. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996;384:83-87. https://doi.org/10.1038/384083a0

37. Ross RA. Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 2003;140:790-801. https://doi.org/10.1038/sj.bjp.0705467

38. Spicarova D, Palecek J. The role of the TRPV1 endogenous agonist N-Oleoyldopamine in modulation of nociceptive signaling at the spinal cord level. J Neurophysiol 2009;102:234-243. https://doi.org/10.1152/jn.00024.2009

39. van der Stelt M, Trevisani M, Vellani V, De Petrocellis L, Schiano Moriello A, Campi B, McNaughton P, ET AL. Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. EMBO J 2005;24:3026-3037. https://doi.org/10.1038/sj.emboj.7600784

40. Goncalves Dos Santos G, Li R, Ng MPE, Lemes JBP, Vieira WF, Nagy I, Tambeli CH, Parada CA. CB1 receptor-dependent desensitisation of TRPV1 channels contributes to the analgesic effect of dipyrone in sensitised primary sensory neurons. Br J Pharmacol 2020;177:4615-4626. https://doi.org/10.1111/bph.15170

41. Bhave G, Hu HJ, Glauner KS, Zhu W, Wang H, Brasier DJ, Oxford GS, Gereau RW 4th. Protein kinase C phosphorylation sensitizes but does not activate the capsaicin receptor transient receptor potential vanilloid 1 (TRPV1). Proc Natl Acad Sci U S A 2003;100:12480-12485. https://doi.org/10.1073/pnas.2032100100

42. Evans RM, Scott RH, Ross RA. Multiple actions of anandamide on neonatal rat cultured sensory neurones. Br J Pharmacol 2004;141:1223-1233. https://doi.org/10.1038/sj.bjp.0705723

43. Khasabova IA, Simone DA, Seybold VS. Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats. Neuroscience 2002;115:613-625. https://doi.org/10.1016/S0306-4522(02)00449-9

44. Farquhar-Smith WP, Egertova M, Bradbury EJ, McMahon SB, Rice AS, Elphick MR. Cannabinoid CB(1) receptor expression in rat spinal cord. Mol Cell Neurosci 2000;15:510-521. https://doi.org/10.1006/mcne.2000.0844

45. Ahluwalia J, Urban L, Capogna M, Bevan S, Nagy I. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience 2000;100:685-688. https://doi.org/10.1016/S0306-4522(00)00389-4

46. Binzen U, Greffrath W, Hennessy S, Bausen M, Saaler-Reinhardt S, Treede RD. Co-expression of the voltage-gated potassium channel Kv1.4 with transient receptor potential channels (TRPV1 and TRPV2) and the cannabinoid receptor CB1 in rat dorsal root ganglion neurons. Neuroscience 2006;142:527-539. https://doi.org/10.1016/j.neuroscience.2006.06.020

47. Hermann H, De Petrocellis L, Bisogno T, Schiano Moriello A, Lutz B, Di Marzo V. Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response. Cell Mol Life Sci 2003;60:607-616. https://doi.org/10.1007/s000180300052

48. Koh DS, Stratiievska A, Jana S, Otto SC, Swanson TM, Nhim A, Carlson S, ET AL. OptoPI3K, genetic code expansion, and click chemistry reveal mechanisms underlying reciprocal regulation between TRPV1 and PI3K. bioRxiv: the preprint server for biology 2023. https://doi.org/10.7554/eLife.91012.1

49. Li T, Wang G, Hui VCC, Saad D, de Sousa Valente J, La Montanara P, Nagy I. TRPV1 feed-forward sensitisation depends on COX2 upregulation in primary sensory neurons. Sci Rep 2021;11:3514. https://doi.org/10.1038/s41598-021-82829-6

50. Spicarova D, Nerandzic V, Palecek J. Update on the role of spinal cord TRPV1 receptors in pain modulation. Physiol Res 2014;63(Suppl 1):S225-S236. https://doi.org/10.33549/physiolres.932713

51. Joseph J, Qu L, Wang S, Kim M, Bennett D, Ro J, Caterina MJ, Chung MK. Phosphorylation of TRPV1 S801 Contributes to Modality-Specific Hyperalgesia in Mice. J Neurosci 2019;39:9954-9966. https://doi.org/10.1523/JNEUROSCI.1064-19.2019

52. Adamek P, Heles M, Palecek J. Mechanical allodynia and enhanced responses to capsaicin are mediated by PI3K in a paclitaxel model of peripheral neuropathy. Neuropharmacology 2019;146:163-174. https://doi.org/10.1016/j.neuropharm.2018.11.027

53. Koivisto AP, Belvisi MG, Gaudet R, Szallasi A. Advances in TRP channel drug discovery: from target validation to clinical studies. Nat Rev Drug Discov 2022;21:41-59. https://doi.org/10.1038/s41573-021-00268-4

54. Fioravanti B, De Felice M, Stucky CL, Medler KA, Luo MC, Gardell LR, Ibrahim M, ET AL. Constitutive activity at the cannabinoid CB1 receptor is required for behavioral response to noxious chemical stimulation of TRPV1: antinociceptive actions of CB1 inverse agonists. J Neurosci 2008;28:11593-11602. https://doi.org/10.1523/JNEUROSCI.3322-08.2008

55. Chen J, Varga A, Selvarajah S, Jenes A, Dienes B, Sousa-Valente J, Kulik A, ET AL. Spatial Distribution of the Cannabinoid Type 1 and Capsaicin Receptors May Contribute to the Complexity of Their Crosstalk. Sci Rep 2016;6:33307. https://doi.org/10.1038/srep33307

56. Fischbach T, Greffrath W, Nawrath H, Treede RD. Effects of anandamide and noxious heat on intracellular calcium concentration in nociceptive drg neurons of rats. J Neurophysiol 2007;98:929-938. https://doi.org/10.1152/jn.01096.2006

57. Mahmud A, Santha P, Paule CC, Nagy I. Cannabinoid 1 receptor activation inhibits transient receptor potential vanilloid type 1 receptor-mediated cationic influx into rat cultured primary sensory neurons. Neuroscience 2009;162:1202-1211. https://doi.org/10.1016/j.neuroscience.2009.05.024

58. Tognetto M, Amadesi S, Harrison S, Creminon C, Trevisani M, Carreras M, Matera M, ET AL. Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J Neurosci 2001;21:1104-1109. https://doi.org/10.1523/JNEUROSCI.21-04-01104.2001

59. Lever IJ, Malcangio M. CB(1) receptor antagonist SR141716A increases capsaicin-evoked release of Substance P from the adult mouse spinal cord. Br J Pharmacol 2002;135:21-24. https://doi.org/10.1038/sj.bjp.0704506

60. Bogdan DM, Studholme K, DiBua A, Gordon C, Kanjiya MP, Yu M, Puopolo M, Kaczocha M. FABP5 deletion in nociceptors augments endocannabinoid signaling and suppresses TRPV1 sensitization and inflammatory pain. Sci Rep 2022;12:9241. https://doi.org/10.1038/s41598-022-13284-0

61. Mackie K, Lai Y, Westenbroek R, Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 1995;15:6552-6561. https://doi.org/10.1523/JNEUROSCI.15-10-06552.1995

62. Mackie K. Mechanisms of CB1 receptor signaling: endocannabinoid modulation of synaptic strength. Int J Obes (Lond) 2006;30(Suppl 1):S19-S23. https://doi.org/10.1038/sj.ijo.0803273

63. Felder CC, Joyce KE, Briley EM, Glass M, Mackie KP, Fahey KJ, Cullinan GJ, ET AL. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther 1998;284:291-297.

64. Rhee MH, Bayewitch M, Avidor-Reiss T, Levy R, Vogel Z. Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. J Neurochem 1998;71:1525-1534. https://doi.org/10.1046/j.1471-4159.1998.71041525.x

65. Baccei ML, Bardoni R, Fitzgerald M. Development of nociceptive synaptic inputs to the neonatal rat dorsal horn: glutamate release by capsaicin and menthol. J Physiol 2003;549:231-242. https://doi.org/10.1113/jphysiol.2003.040451

66. Yang K, Kumamoto E, Furue H, Li YQ, Yoshimura M. Action of capsaicin on dorsal root-evoked synaptic transmission to substantia gelatinosa neurons in adult rat spinal cord slices. Brain Res 1999;830:268-273. https://doi.org/10.1016/S0006-8993(99)01408-0

67. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997;389:816-824. https://doi.org/10.1038/39807

68. Kelly S, Chapman V. Spinal administration of capsazepine inhibits noxious evoked responses of dorsal horn neurons in non-inflamed and carrageenan inflamed rats. Brain Res 2002;935:103-108. https://doi.org/10.1016/S0006-8993(02)02552-0

69. Morisset V, Urban L. Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord. J Neurophysiol 2001;86:40-48. https://doi.org/10.1152/jn.2001.86.1.40

70. Luo C, Kumamoto E, Furue H, Chen J, Yoshimura M. Anandamide inhibits excitatory transmission to rat substantia gelatinosa neurones in a manner different from that of capsaicin. Neurosci Lett 2002;321:17-20. https://doi.org/10.1016/S0304-3940(01)02471-5

71. Morisset V, Ahluwalia J, Nagy I, Urban L. Possible mechanisms of cannabinoid-induced antinociception in the spinal cord. Eur J Pharmacol 2001;429:93-100. https://doi.org/10.1016/S0014-2999(01)01309-7

72. Spicarova D, Nerandzic V, Muzik D, Pontearso M, Bhattacharyya A, Nagy I, Palecek J. Inhibition of synaptic transmission by anandamide precursor 20:4-NAPE is mediated by TRPV1 receptors under inflammatory conditions. Front Mol Neurosci 2023;16:1188503. https://doi.org/10.3389/fnmol.2023.1188503

73. Nyilas R, Gregg LC, Mackie K, Watanabe M, Zimmer A, Hohmann AG, Katona I. Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia. Eur Neurosci 2009;29:1964-1978. https://doi.org/10.1111/j.1460-9568.2009.06751.x

74. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001;410:588-592. https://doi.org/10.1038/35069076

75. Kreitzer AC, Regehr WG. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 2001;29:717-727. https://doi.org/10.1016/S0896-6273(01)00246-X

76. Kato A, Punnakkal P, Pernia-Andrade AJ, von Schoultz C, Sharopov S, Nyilas R, Katona I, Zeilhofer HU. Endocannabinoid-dependent plasticity at spinal nociceptor synapses. J Physiol 2012;590:4717-4733. https://doi.org/10.1113/jphysiol.2012.234229

77. Pernia-Andrade AJ, Kato A, Witschi R, Nyilas R, Katona I, Freund TF, Watanabe M, ET AL. Spinal endocannabinoids and CB1 receptors mediate C-fiber-induced heterosynaptic pain sensitization. Science 2009;325:760-764. https://doi.org/10.1126/science.1171870

78. Veress G, Meszar Z, Muszil D, Avelino A, Matesz K, Mackie K, Nagy I. Characterisation of cannabinoid 1 receptor expression in the perikarya, and peripheral and spinal processes of primary sensory neurons. Brain Struct Funct 2013;218:733-750. https://doi.org/10.1007/s00429-012-0425-2

79. Hegyi Z, Kis G, Hollo K, Ledent C, Antal M. Neuronal and glial localization of the cannabinoid-1 receptor in the superficial spinal dorsal horn of the rodent spinal cord. Eur J Neurosci 2009;30:251-262. https://doi.org/10.1111/j.1460-9568.2009.06816.x

80. Woodhams SG, Sagar DR, Burston JJ, Chapman V. The role of the endocannabinoid system in pain. Handb Exp Pharmacol 2015;227:119-143. https://doi.org/10.1007/978-3-662-46450-2_7

81. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, Rubino T, ET AL. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 2007;10:870-879. https://doi.org/10.1038/nn1916

82. Richardson JD, Aanonsen L, Hargreaves KM. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol 1997;319:R3-4. https://doi.org/10.1016/S0014-2999(96)00952-1

83. Chapman V. The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat. Br J Pharmacol 1999;127:1765-1767. https://doi.org/10.1038/sj.bjp.0702758

84. Dogrul A, Gul H, Akar A, Yildiz O, Bilgin F, Guzeldemir E. Topical cannabinoid antinociception: synergy with spinal sites. Pain 2003;105:11-16. https://doi.org/10.1016/S0304-3959(03)00068-X

85. Harris J, Drew LJ, Chapman V. Spinal anandamide inhibits nociceptive transmission via cannabinoid receptor activation in vivo. Neuroreport 2000;11:2817-2819. https://doi.org/10.1097/00001756-200008210-00041

86. Martin WJ, Loo CM, Basbaum AI. Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain 1999;82:199-205. https://doi.org/10.1016/S0304-3959(99)00045-7

87. Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L, James I. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 2001;92:91-100. https://doi.org/10.1016/S0304-3959(00)00474-7

88. Petrosino S, Palazzo E, de Novellis V, Bisogno T, Rossi F, Maione S, Di Marzo V. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 2007;52:415-422. https://doi.org/10.1016/j.neuropharm.2006.08.011

89. Richardson JD, Aanonsen L, Hargreaves KM. Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 1998;345:145-153. https://doi.org/10.1016/S0014-2999(97)01621-X

90. Starowicz K, Makuch W, Osikowicz M, Piscitelli F, Petrosino S, Di Marzo V, Przewlocka B. Spinal anandamide produces analgesia in neuropathic rats: possible CB(1)- and TRPV1-mediated mechanisms. Neuropharmacology 2012;62:1746-1755. https://doi.org/10.1016/j.neuropharm.2011.11.021

91. Starowicz K, Makuch W, Korostynski M, Malek N, Slezak M, Zychowska M, Petrosino S, ET AL. Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism. PLoS One 2013;8:e60040. https://doi.org/10.1371/journal.pone.0060040

92. Serpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, Ehler E. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur J Pain 2014;18:999-1012. https://doi.org/10.1002/j.1532-2149.2013.00445.x

93. Perras C. Sativex for the management of multiple sclerosis symptoms. Issues Emerg Health Technol 2005:(72):1-4.

94. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 2001;98:9371-9376. https://doi.org/10.1073/pnas.161191698

95. Jhaveri MD, Richardson D, Kendall DA, Barrett DA, Chapman V. Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 2006;26:13318-13327. https://doi.org/10.1523/JNEUROSCI.3326-06.2006

96. Di Marzo V. New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov 2018;17:623-639. https://doi.org/10.1038/nrd.2018.115

97. Huggins JP, Smart TS, Langman S, Taylor L, Young T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 2012;153:1837-1846. https://doi.org/10.1016/j.pain.2012.04.020

98. Mallet C, Dubray C, Duale C. FAAH inhibitors in the limelight, but regrettably. Int J Clin Pharmacol Ther 2016;54:498-501. https://doi.org/10.5414/CP202687

99. van Esbroeck ACM, Janssen APA, Cognetta AB 3rd, Ogasawara D, Shpak G, van der Kroeg M, Kantae V, ET AL. Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science 2017;356:1084-1087. https://doi.org/10.1126/science.aaf7497

100. Rocha JF, Santos A, Gama H, Moser P, Falcao A, Pressman P, Wallace Hayes A, Soares-da-Silva P. Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10-2474: A Double-Blind, Randomized, Placebo-Controlled Study in Healthy Volunteers. Clin Pharmacol Ther 2022;111:391-403. https://doi.org/10.1002/cpt.2290

101. Kalliomaki J, Annas P, Huizar K, Clarke C, Zettergren A, Karlsten R, Segerdahl M. Evaluation of the analgesic efficacy and psychoactive effects of AZD1940, a novel peripherally acting cannabinoid agonist, in human capsaicin-induced pain and hyperalgesia. Clin Exp Pharmacol Physiol 2013;40:212-218. https://doi.org/10.1111/1440-1681.12051

102. Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease--successes and failures. FEBS J 2013;280:1918-1943. https://doi.org/10.1111/febs.12260

103. Milligan AL, Szabo-Pardi TA, Burton MD. Cannabinoid Receptor Type 1 and Its Role as an Analgesic: An Opioid Alternative? J Dual Diagn 2020;16:106-119. https://doi.org/10.1080/15504263.2019.1668100